Share Price and Basic Stock Data
Last Updated: December 17, 2025, 9:09 pm
| PEG Ratio | -5.67 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gufic BioSciences Ltd operates within the pharmaceutical sector, primarily focusing on manufacturing and marketing a diverse range of pharmaceutical products. For the financial year ending March 2025, the company reported sales of ₹820 Cr, a modest increase from ₹807 Cr in the previous year, indicating a steady growth trajectory. Over the past year, quarterly sales have shown resilience, with a notable uptick in the last few quarters, peaking at ₹215 Cr in September 2023. This upward trend in revenue is indicative of a robust demand for Gufic’s offerings, reflecting the company’s ability to navigate market challenges effectively. However, the sales figures also highlight a slight dip in momentum towards the end of the fiscal year, with sales declining to ₹195 Cr in March 2025. This could raise questions about seasonal fluctuations or potential competitive pressures in the market.
Profitability and Efficiency Metrics
When we analyze profitability, Gufic BioSciences presents a mixed picture. The operating profit margin (OPM) for FY 2025 stood at 17%, which, while respectable, shows a decline from the previous year’s margin of 19%. This contraction in margins, despite the increase in sales, suggests rising costs or pricing pressures that could affect overall profitability. The net profit for FY 2025 was reported at ₹70 Cr, down from ₹86 Cr in FY 2024, marking a concerning trend in bottom-line performance. The return on equity (ROE) and return on capital employed (ROCE) metrics also reflect this struggle, with ROE at 11.58% and ROCE at 14.99%. In a sector where margins can be tight, maintaining efficiency is crucial. The cash conversion cycle has stretched to 197 days, indicating a potential liquidity concern as it reflects longer times to convert investments in inventory and receivables back into cash.
Balance Sheet Strength and Financial Ratios
Gufic’s balance sheet reveals a blend of strengths and vulnerabilities. As of March 2025, the company reported total borrowings of ₹369 Cr against reserves of ₹619 Cr, illustrating a relatively healthy reserve cushion compared to its debt levels. The debt-to-equity ratio stands at 0.51, which is manageable and suggests that Gufic is not over-leveraged. However, the interest coverage ratio (ICR) at 5.98 indicates that while the company can cover its interest obligations comfortably, it has declined from the previous year’s 9.64, raising a flag over potential future profitability pressures. The price-to-book value ratio of 5.61x suggests that the stock might be trading at a premium compared to its book value, which could deter value-focused investors. Collectively, these financial ratios portray a company that is navigating growth while grappling with rising costs and profitability concerns.
Shareholding Pattern and Investor Confidence
The shareholding structure of Gufic BioSciences Ltd reflects significant promoter confidence, with promoters holding 72.50% of the equity as of September 2025. This high level of promoter ownership can be reassuring for retail investors, indicating that the management has substantial skin in the game. However, foreign institutional investors (FIIs) remain hesitant, holding only 0.33% of the company, which could signal a lack of broader market confidence in the stock. Domestic institutional investors (DIIs) have gradually increased their stake to 3.66%, suggesting a cautious optimism among local funds. The total number of shareholders has declined to 31,420, which may indicate a consolidation of ownership or investor fatigue. This dynamic could reflect the market’s mixed perception of Gufic’s growth prospects, especially amid recent profitability challenges.
Outlook, Risks, and Final Insight
Looking ahead, Gufic BioSciences faces a landscape filled with both opportunities and challenges. The pharmaceutical sector is poised for growth, driven by increasing healthcare demands, yet Gufic must address its declining margins and stretched cash conversion cycle to sustain investor confidence. Key risks include potential cost pressures and the need to manage its inventory and receivables more effectively. The company’s ability to innovate and expand its product portfolio will be critical in maintaining its competitive edge. Investors should watch for any strategic moves by management to enhance operational efficiency and profitability. Overall, while Gufic has the foundation for growth, its future success hinges on navigating the current challenges effectively and maintaining robust financial health.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 143 Cr. | 114 | 235/84.3 | 31.7 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,240 Cr. | 389 | 479/192 | 87.8 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 31.8 Cr. | 42.9 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 46.9 Cr. | 32.0 | 32.0/17.0 | 112 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,299.53 Cr | 1,144.52 | 51.48 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 165 | 175 | 177 | 173 | 195 | 215 | 202 | 195 | 203 | 204 | 208 | 205 | 227 |
| Expenses | 132 | 142 | 143 | 141 | 160 | 176 | 165 | 161 | 167 | 166 | 174 | 178 | 195 |
| Operating Profit | 33 | 33 | 34 | 32 | 35 | 39 | 36 | 34 | 36 | 39 | 34 | 27 | 32 |
| OPM % | 20% | 19% | 19% | 19% | 18% | 18% | 18% | 18% | 18% | 19% | 16% | 13% | 14% |
| Other Income | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 |
| Interest | 1 | 2 | 2 | 3 | 4 | 4 | 3 | 4 | 5 | 5 | 5 | 8 | 9 |
| Depreciation | 4 | 5 | 6 | 6 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 8 | 8 |
| Profit before tax | 28 | 27 | 27 | 24 | 28 | 31 | 30 | 27 | 28 | 29 | 26 | 11 | 16 |
| Tax % | 26% | 26% | 25% | 24% | 26% | 25% | 25% | 26% | 26% | 26% | 26% | 26% | 26% |
| Net Profit | 21 | 20 | 20 | 18 | 21 | 23 | 22 | 20 | 21 | 22 | 19 | 8 | 12 |
| EPS in Rs | 2.17 | 2.08 | 2.10 | 1.87 | 2.13 | 2.39 | 2.22 | 2.00 | 2.08 | 2.17 | 1.93 | 0.79 | 1.20 |
Last Updated: August 20, 2025, 10:00 am
Below is a detailed analysis of the quarterly data for Gufic BioSciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 227.00 Cr.. The value appears strong and on an upward trend. It has increased from 205.00 Cr. (Mar 2025) to 227.00 Cr., marking an increase of 22.00 Cr..
- For Expenses, as of Jun 2025, the value is 195.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 178.00 Cr. (Mar 2025) to 195.00 Cr., marking an increase of 17.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 32.00 Cr.. The value appears strong and on an upward trend. It has increased from 27.00 Cr. (Mar 2025) to 32.00 Cr., marking an increase of 5.00 Cr..
- For OPM %, as of Jun 2025, the value is 14.00%. The value appears strong and on an upward trend. It has increased from 13.00% (Mar 2025) to 14.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 9.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 8.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Mar 2025) to 16.00 Cr., marking an increase of 5.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 26.00%.
- For Net Profit, as of Jun 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 4.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.20. The value appears strong and on an upward trend. It has increased from 0.79 (Mar 2025) to 1.20, marking an increase of 0.41.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:17 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 121 | 148 | 201 | 245 | 306 | 351 | 379 | 488 | 779 | 691 | 807 | 820 | 870 |
| Expenses | 109 | 134 | 181 | 222 | 267 | 305 | 327 | 404 | 631 | 556 | 657 | 683 | 741 |
| Operating Profit | 12 | 14 | 20 | 23 | 39 | 46 | 52 | 84 | 148 | 135 | 150 | 136 | 129 |
| OPM % | 10% | 10% | 10% | 9% | 13% | 13% | 14% | 17% | 19% | 20% | 19% | 17% | 15% |
| Other Income | 1 | 1 | 1 | 1 | 4 | 4 | 6 | 4 | 3 | 3 | -0 | 4 | 5 |
| Interest | 4 | 4 | 6 | 6 | 9 | 10 | 14 | 14 | 5 | 8 | 17 | 25 | 32 |
| Depreciation | 2 | 4 | 4 | 4 | 4 | 5 | 14 | 16 | 19 | 22 | 17 | 21 | 28 |
| Profit before tax | 6 | 7 | 10 | 14 | 30 | 35 | 30 | 58 | 127 | 107 | 116 | 94 | 74 |
| Tax % | 32% | 36% | 29% | 37% | 45% | 38% | 25% | 23% | 24% | 25% | 26% | 26% | |
| Net Profit | 4 | 4 | 7 | 9 | 16 | 22 | 23 | 44 | 96 | 80 | 86 | 70 | 54 |
| EPS in Rs | 0.55 | 0.54 | 0.95 | 1.17 | 2.13 | 2.82 | 2.92 | 5.68 | 9.89 | 8.22 | 8.59 | 6.97 | 5.41 |
| Dividend Payout % | 9% | 9% | 5% | 4% | 2% | 2% | 2% | 2% | 1% | 1% | 1% | 1% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 75.00% | 28.57% | 77.78% | 37.50% | 4.55% | 91.30% | 118.18% | -16.67% | 7.50% | -18.60% |
| Change in YoY Net Profit Growth (%) | 0.00% | 75.00% | -46.43% | 49.21% | -40.28% | -32.95% | 86.76% | 26.88% | -134.85% | 24.17% | -26.10% |
Gufic BioSciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 17% |
| 3 Years: | 2% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 33% |
| 5 Years: | 25% |
| 3 Years: | -10% |
| TTM: | -29% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 35% |
| 3 Years: | 16% |
| 1 Year: | -7% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 22% |
| 3 Years: | 18% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 5:30 am
Balance Sheet
Last Updated: December 4, 2025, 1:19 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 18 | 19 | 26 | 30 | 46 | 68 | 120 | 164 | 259 | 338 | 523 | 591 | 619 |
| Borrowings | 33 | 33 | 43 | 57 | 80 | 98 | 126 | 62 | 64 | 334 | 333 | 336 | 369 |
| Other Liabilities | 52 | 67 | 75 | 84 | 104 | 106 | 152 | 157 | 188 | 179 | 227 | 232 | 271 |
| Total Liabilities | 111 | 127 | 152 | 178 | 238 | 280 | 408 | 392 | 521 | 861 | 1,093 | 1,170 | 1,268 |
| Fixed Assets | 30 | 25 | 22 | 22 | 23 | 24 | 83 | 100 | 115 | 160 | 159 | 506 | 495 |
| CWIP | 0 | 0 | 0 | 0 | 2 | 10 | 31 | 13 | 41 | 170 | 307 | 22 | 24 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 3 |
| Other Assets | 81 | 102 | 130 | 156 | 213 | 245 | 294 | 279 | 365 | 531 | 625 | 639 | 747 |
| Total Assets | 111 | 127 | 152 | 178 | 238 | 280 | 408 | 392 | 521 | 861 | 1,093 | 1,170 | 1,268 |
Below is a detailed analysis of the balance sheet data for Gufic BioSciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Reserves, as of Sep 2025, the value is 619.00 Cr.. The value appears strong and on an upward trend. It has increased from 591.00 Cr. (Mar 2025) to 619.00 Cr., marking an increase of 28.00 Cr..
- For Borrowings, as of Sep 2025, the value is 369.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 336.00 Cr. (Mar 2025) to 369.00 Cr., marking an increase of 33.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 271.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 232.00 Cr. (Mar 2025) to 271.00 Cr., marking an increase of 39.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,268.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,170.00 Cr. (Mar 2025) to 1,268.00 Cr., marking an increase of 98.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 495.00 Cr.. The value appears to be declining and may need further review. It has decreased from 506.00 Cr. (Mar 2025) to 495.00 Cr., marking a decrease of 11.00 Cr..
- For CWIP, as of Sep 2025, the value is 24.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Mar 2025) to 24.00 Cr., marking an increase of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Other Assets, as of Sep 2025, the value is 747.00 Cr.. The value appears strong and on an upward trend. It has increased from 639.00 Cr. (Mar 2025) to 747.00 Cr., marking an increase of 108.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,268.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,170.00 Cr. (Mar 2025) to 1,268.00 Cr., marking an increase of 98.00 Cr..
Notably, the Reserves (619.00 Cr.) exceed the Borrowings (369.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -21.00 | -19.00 | -23.00 | -34.00 | -41.00 | -52.00 | -74.00 | 22.00 | 84.00 | -199.00 | -183.00 | -200.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 85 | 82 | 102 | 78 | 97 | 107 | 103 | 93 | 71 | 109 | 149 | 140 |
| Inventory Days | 144 | 165 | 180 | 190 | 238 | 190 | 249 | 138 | 102 | 202 | 188 | 211 |
| Days Payable | 176 | 223 | 188 | 132 | 192 | 157 | 238 | 162 | 125 | 143 | 156 | 155 |
| Cash Conversion Cycle | 54 | 25 | 94 | 136 | 143 | 141 | 114 | 69 | 48 | 167 | 181 | 197 |
| Working Capital Days | 20 | 4 | 18 | 14 | 26 | 40 | 17 | 63 | 50 | 68 | 97 | 93 |
| ROCE % | 17% | 18% | 24% | 24% | 33% | 30% | 21% | 29% | 46% | 23% | 17% | 13% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| ICICI Prudential Multicap Fund | 1,480,998 | 0.33 | 52.67 | N/A | N/A | N/A |
| SBI Healthcare Opportunities Fund | 1,000,000 | 0.86 | 35.57 | 1,000,000 | 2025-04-22 17:25:34 | 0% |
| ICICI Prudential Smallcap Fund | 446,517 | 0.19 | 15.88 | 441,293 | 2025-12-15 09:10:00 | 1.18% |
| Bank of India Small Cap Fund | 348,463 | 0.63 | 12.39 | N/A | N/A | N/A |
| ICICI Prudential ELSS Tax Saver Fund | 74,008 | 0.02 | 2.63 | N/A | N/A | N/A |
| ICICI Prudential Bharat Consumption Fund | 32,021 | 0.03 | 1.14 | 4,993 | 2025-12-15 09:10:00 | 541.32% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 1.00 | 1.00 |
| Basic EPS (Rs.) | 6.95 | 8.74 |
| Diluted EPS (Rs.) | 6.95 | 8.74 |
| Cash EPS (Rs.) | 9.05 | 10.29 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 59.94 | 53.11 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 59.94 | 53.11 |
| Revenue From Operations / Share (Rs.) | 81.75 | 80.44 |
| PBDIT / Share (Rs.) | 13.79 | 14.76 |
| PBIT / Share (Rs.) | 11.69 | 13.07 |
| PBT / Share (Rs.) | 9.39 | 11.54 |
| Net Profit / Share (Rs.) | 6.95 | 8.59 |
| NP After MI And SOA / Share (Rs.) | 6.95 | 8.59 |
| PBDIT Margin (%) | 16.87 | 18.35 |
| PBIT Margin (%) | 14.30 | 16.24 |
| PBT Margin (%) | 11.48 | 14.33 |
| Net Profit Margin (%) | 8.49 | 10.67 |
| NP After MI And SOA Margin (%) | 8.49 | 10.67 |
| Return on Networth / Equity (%) | 11.58 | 16.17 |
| Return on Capital Employeed (%) | 14.99 | 18.18 |
| Return On Assets (%) | 5.95 | 7.88 |
| Long Term Debt / Equity (X) | 0.21 | 0.28 |
| Total Debt / Equity (X) | 0.51 | 0.59 |
| Asset Turnover Ratio (%) | 0.72 | 0.00 |
| Current Ratio (X) | 1.61 | 1.61 |
| Quick Ratio (X) | 1.05 | 1.08 |
| Inventory Turnover Ratio (X) | 1.65 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 1.12 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.93 |
| Earning Retention Ratio (%) | 0.00 | 98.88 |
| Cash Earning Retention Ratio (%) | 0.00 | 99.07 |
| Interest Coverage Ratio (X) | 5.98 | 9.64 |
| Interest Coverage Ratio (Post Tax) (X) | 4.01 | 6.61 |
| Enterprise Value (Cr.) | 3655.21 | 3142.92 |
| EV / Net Operating Revenue (X) | 4.46 | 3.90 |
| EV / EBITDA (X) | 26.43 | 21.23 |
| MarketCap / Net Operating Revenue (X) | 4.12 | 3.52 |
| Retention Ratios (%) | 0.00 | 98.87 |
| Price / BV (X) | 5.61 | 5.33 |
| Price / Net Operating Revenue (X) | 4.12 | 3.52 |
| EarningsYield | 0.02 | 0.03 |
After reviewing the key financial ratios for Gufic BioSciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.74 (Mar 24) to 6.95, marking a decrease of 1.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.74 (Mar 24) to 6.95, marking a decrease of 1.79.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.05. This value is within the healthy range. It has decreased from 10.29 (Mar 24) to 9.05, marking a decrease of 1.24.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 59.94. It has increased from 53.11 (Mar 24) to 59.94, marking an increase of 6.83.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 59.94. It has increased from 53.11 (Mar 24) to 59.94, marking an increase of 6.83.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 81.75. It has increased from 80.44 (Mar 24) to 81.75, marking an increase of 1.31.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.79. This value is within the healthy range. It has decreased from 14.76 (Mar 24) to 13.79, marking a decrease of 0.97.
- For PBIT / Share (Rs.), as of Mar 25, the value is 11.69. This value is within the healthy range. It has decreased from 13.07 (Mar 24) to 11.69, marking a decrease of 1.38.
- For PBT / Share (Rs.), as of Mar 25, the value is 9.39. This value is within the healthy range. It has decreased from 11.54 (Mar 24) to 9.39, marking a decrease of 2.15.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.59 (Mar 24) to 6.95, marking a decrease of 1.64.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.59 (Mar 24) to 6.95, marking a decrease of 1.64.
- For PBDIT Margin (%), as of Mar 25, the value is 16.87. This value is within the healthy range. It has decreased from 18.35 (Mar 24) to 16.87, marking a decrease of 1.48.
- For PBIT Margin (%), as of Mar 25, the value is 14.30. This value is within the healthy range. It has decreased from 16.24 (Mar 24) to 14.30, marking a decrease of 1.94.
- For PBT Margin (%), as of Mar 25, the value is 11.48. This value is within the healthy range. It has decreased from 14.33 (Mar 24) to 11.48, marking a decrease of 2.85.
- For Net Profit Margin (%), as of Mar 25, the value is 8.49. This value is within the healthy range. It has decreased from 10.67 (Mar 24) to 8.49, marking a decrease of 2.18.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.49. This value is within the healthy range. It has decreased from 10.67 (Mar 24) to 8.49, marking a decrease of 2.18.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.58. This value is below the healthy minimum of 15. It has decreased from 16.17 (Mar 24) to 11.58, marking a decrease of 4.59.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.99. This value is within the healthy range. It has decreased from 18.18 (Mar 24) to 14.99, marking a decrease of 3.19.
- For Return On Assets (%), as of Mar 25, the value is 5.95. This value is within the healthy range. It has decreased from 7.88 (Mar 24) to 5.95, marking a decrease of 1.93.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.21. This value is within the healthy range. It has decreased from 0.28 (Mar 24) to 0.21, marking a decrease of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.51. This value is within the healthy range. It has decreased from 0.59 (Mar 24) to 0.51, marking a decrease of 0.08.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.72. It has increased from 0.00 (Mar 24) to 0.72, marking an increase of 0.72.
- For Current Ratio (X), as of Mar 25, the value is 1.61. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.61.
- For Quick Ratio (X), as of Mar 25, the value is 1.05. This value is within the healthy range. It has decreased from 1.08 (Mar 24) to 1.05, marking a decrease of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.65. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 1.65, marking an increase of 1.65.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 1.12 (Mar 24) to 0.00, marking a decrease of 1.12.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 0.93 (Mar 24) to 0.00, marking a decrease of 0.93.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 98.88 (Mar 24) to 0.00, marking a decrease of 98.88.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 99.07 (Mar 24) to 0.00, marking a decrease of 99.07.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.98. This value is within the healthy range. It has decreased from 9.64 (Mar 24) to 5.98, marking a decrease of 3.66.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.01. This value is within the healthy range. It has decreased from 6.61 (Mar 24) to 4.01, marking a decrease of 2.60.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,655.21. It has increased from 3,142.92 (Mar 24) to 3,655.21, marking an increase of 512.29.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.46. This value exceeds the healthy maximum of 3. It has increased from 3.90 (Mar 24) to 4.46, marking an increase of 0.56.
- For EV / EBITDA (X), as of Mar 25, the value is 26.43. This value exceeds the healthy maximum of 15. It has increased from 21.23 (Mar 24) to 26.43, marking an increase of 5.20.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.12. This value exceeds the healthy maximum of 3. It has increased from 3.52 (Mar 24) to 4.12, marking an increase of 0.60.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 98.87 (Mar 24) to 0.00, marking a decrease of 98.87.
- For Price / BV (X), as of Mar 25, the value is 5.61. This value exceeds the healthy maximum of 3. It has increased from 5.33 (Mar 24) to 5.61, marking an increase of 0.28.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.12. This value exceeds the healthy maximum of 3. It has increased from 3.52 (Mar 24) to 4.12, marking an increase of 0.60.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gufic BioSciences Ltd:
- Net Profit Margin: 8.49%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.99% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.58% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.01
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.05
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 64.4 (Industry average Stock P/E: 51.48)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.51
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.49%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 37, First Floor, Kamala Bhavan II, Mumbai Maharashtra 400069 | corporaterelations@guficbio.com http://www.gufic.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Jayesh P Choksi | Chairman & Managing Director |
| Mr. Pranav J Choksi | WholeTime Director & CEO |
| Mr. Pankaj J Gandhi | Whole Time Director |
| Dr. Anu S Auora | Independent Director |
| Mr. Kamal K Seth | Independent Director |
| Mr. Akshya Kumar Mahapatra | Independent Director |
FAQ
What is the intrinsic value of Gufic BioSciences Ltd?
Gufic BioSciences Ltd's intrinsic value (as of 18 December 2025) is 397.45 which is 13.88% higher the current market price of 349.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 3,498 Cr. market cap, FY2025-2026 high/low of 498/285, reserves of ₹619 Cr, and liabilities of 1,268 Cr.
What is the Market Cap of Gufic BioSciences Ltd?
The Market Cap of Gufic BioSciences Ltd is 3,498 Cr..
What is the current Stock Price of Gufic BioSciences Ltd as on 18 December 2025?
The current stock price of Gufic BioSciences Ltd as on 18 December 2025 is 349.
What is the High / Low of Gufic BioSciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gufic BioSciences Ltd stocks is 498/285.
What is the Stock P/E of Gufic BioSciences Ltd?
The Stock P/E of Gufic BioSciences Ltd is 64.4.
What is the Book Value of Gufic BioSciences Ltd?
The Book Value of Gufic BioSciences Ltd is 62.7.
What is the Dividend Yield of Gufic BioSciences Ltd?
The Dividend Yield of Gufic BioSciences Ltd is 0.03 %.
What is the ROCE of Gufic BioSciences Ltd?
The ROCE of Gufic BioSciences Ltd is 13.2 %.
What is the ROE of Gufic BioSciences Ltd?
The ROE of Gufic BioSciences Ltd is 12.3 %.
What is the Face Value of Gufic BioSciences Ltd?
The Face Value of Gufic BioSciences Ltd is 1.00.